Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZN5QX)

• Drug Name: MGD014 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus-1 infection	1C62	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMZN5QX

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[3]
TBC-M4	DM9CDPO	Human immunodeficiency virus infection	1C62	Phase 1	[4]
PENNVAX-6	DM0BNLC	Human immunodeficiency virus infection	1C62	Phase 1	[5]
Ad5-ENVA-48	DMMBQV3	Human immunodeficiency virus-1 infection	1C62	Phase 1	[6]
GPG	DMYR7LO	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1/2	[7]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[8]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[9]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[10]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[11]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[12]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[13]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[14]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[15]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[16]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)	TTEC2T3	ENV_HV1H2	Inhibitor	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03570918) MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of MacroGenics.
• [3] A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
• [4] A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
• [5] Company report (Inovio)
• [6] ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
• [7] GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway. Retrovirology 2010, 7:20.
• [8] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [9] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [10] Clinical pipeline report, company report or official report of Genmab.
• [11] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [12] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [13] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [14] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [15] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [16] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [17] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.